| Drug Name: | BLEPH-10 |
| Manufacturer: | Allergan, Inc. |
| Other Info: | For trachoma: Instill two drops into the conjunctival sac(s) of the affected eye(s) every two hours. Topical administration must be accompanied by systemic administration. |
| Clinical Trials: | |
BLEPH®-10 solution is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species.Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa.
A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.FOR TOPICAL EYE USE ONLY - NOT FOR INJECTION.FATALITIES HAVE OCCURRED, ALTHOUGH RARELY, DUE TO SEVERE REACTIONS TO SULFONAMIDES INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS, APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS.
Sensitizations may recur when a sulfonamide is readministered, irrespective of the route of administration.
Sensitivity reactions have been reported in individuals with no prior history of sulfonamide hypersensitivity.
At the first sign of hypersensitivity, skin rash or other serious reaction, discontinue use of this preparation.